SB1025 would significantly expand Oklahoma’s regulation of pharmacy benefits managers (PBMs), health insurers, and pharmacy benefit arrangements. The bill creates the “Oklahoma Rebate Pass-Through and Pharmacy Benefits Manager Meaningful Transparency Act of 2025,” updates statutory definitions, and adds new disclosure, reporting, licensing, and enforcement requirements. It also reinforces existing protections for pharmacies and consumers by barring spread pricing, limiting certain fees and reimbursement practices, and prohibiting contractual restrictions on pharmacies telling patients about lower-cost generic or cash-pay options.
A major feature of the bill is its point-of-sale rebate pass-through requirement. For both PBMs and insurers, enrollee cost sharing for prescription drugs would have to be calculated using a price reduced by at least 85% of rebates received or expected to be received in connection with the drug. The bill also requires quarterly reporting to the Attorney General on rebates, pass-through amounts, and pharmacy payment data, while allowing the Attorney General to request raw data and adjust reporting frequency. At the same time, the bill treats rebate information as confidential trade secret material and states that it is not subject to the Oklahoma Open Records Act.
The bill further revises formulary governance by requiring pharmacy and therapeutics committees to operate under more detailed conflict-of-interest, transparency, and clinical-review standards. It directs those committees to use evidence-based criteria, review utilization management practices, and consider new FDA-approved drugs within 90 days unless a clinical justification is provided. On the licensing side, it expands PBM licensure requirements with more detailed ownership, management, bond, and background disclosures, and gives both the Insurance Department and the Attorney General authority to investigate, fine, suspend, revoke, or refuse licenses for violations.
The general sentiment reflected by the bill text is strongly pro-transparency and pro-consumer, with a clear emphasis on lowering out-of-pocket prescription drug costs and curbing PBM practices viewed as opaque or anti-competitive. Because there were no committee transcripts or recorded votes provided, there is no direct evidence of debate or opposition in the available materials. However, the structure of the bill suggests likely support from consumer advocates, independent pharmacies, and regulators seeking greater disclosure, while PBMs and insurers may view the reporting, rebate pass-through, and licensing provisions as burdensome and potentially intrusive.
Notable points of contention likely include the 85% rebate pass-through mandate, the ban on spread pricing, the breadth of required disclosures to the Attorney General and insurers, and the confidentiality carve-outs that protect rebate data from public release. The bill also draws a line between regulated PBMs and certain entities that are excluded from the definition, such as employers administering their own self-funded plans and pharmacies offering their own discount programs. Those definitional boundaries, along with the enforcement powers given to the Attorney General and Insurance Commissioner, are likely to be central issues for affected industry participants.
SB1025 would amend Title 36 and Title 59 to impose new PBM and insurer transparency, rebate pass-through, formulary, and licensing requirements. It would create new statutory sections requiring point-of-sale cost-sharing reductions tied to rebates, prohibit spread pricing and certain network fees, expand reporting and audit access, and strengthen enforcement authority for the Attorney General and Insurance Commissioner. The bill would directly affect PBMs, health insurers, self-funded plans, pharmacies, and pharmacy and therapeutics committees, while also making rebate-related information confidential and exempt from public records disclosure.
The bill’s overall tone is reform-oriented and consumer-focused, with a clear policy preference for transparency, rebate pass-through, and lower prescription drug costs. No committee discussion or vote history was provided, so there is no documented floor or committee sentiment to summarize. Based on the text alone, the measure appears designed to appeal to patients, pharmacies, and regulators concerned about PBM practices, while likely drawing resistance from PBMs and insurers that would face new compliance and reporting obligations.
The main points of contention are likely to be the 85% rebate pass-through requirement, the prohibition on spread pricing, and the extensive disclosure and audit provisions imposed on PBMs and insurers. PBMs and health plans may argue that the bill overregulates pricing arrangements, increases administrative burden, and exposes proprietary business information, even though the bill also protects rebate data as trade secret information. Another likely issue is the scope of the definitions and exemptions, especially the treatment of self-funded employers and pharmacy discount programs, which could affect who is subject to the new rules.